Eisai of Japan has completed Phase II testing of its Alzheimer's drugAricept (donepezil) in the treatment of cerebrovascular dementia, a disease which occurs after cerebral thrombosis, and says it will file for approval for this indication with the US Food and Drug Administration in March 2002. Eisai is expecting sales of Aricept to reach around $745 million for the fiscal year to March 2002, but forecasts further growth for the product as there are more sufferers of cerebrovascular dementia than of Alzheimer's, reports Nippon Digital Communications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze